- Home
- EYPT vs FUBO Comparison
EYPT vs FUBO Comparison
Compare EYPT & FUBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | FUBO |
|---|---|---|
| Founded | 1987 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Broadcasting |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.3M | 265.1M |
| IPO Year | 2005 | 2011 |
Fundamental Metrics
Financial Performance| Metric | EYPT | FUBO |
|---|---|---|
| Price | $0.43 | $8.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 10 |
| Target Price | ★ $25.91 | $17.00 |
| AVG Volume (30 Days) | ★ 2.6M | 1.0M |
| Earning Date | 11-04-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,539,000.00 | $4,271,000.00 |
| Revenue This Year | N/A | $40.22 |
| Revenue Next Year | $967.16 | $4.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10317.07 |
| 52 Week Low | $2.93 | $1.02 |
| 52 Week High | $19.11 | $14.54 |
Technical Indicators
Market Signals| Indicator | EYPT | FUBO |
|---|---|---|
| Relative Strength Index (RSI) | 15.08 | 32.23 |
| Support Level | N/A | $1.06 |
| Resistance Level | $3.57 | $10.69 |
| Average True Range (ATR) | 0.20 | 0.44 |
| MACD | -0.04 | -0.08 |
| Stochastic Oscillator | 0.67 | 5.56 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About FUBO fuboTV Inc.
FuboTV Inc is a sports-first, Pay TV replacement product offering subscribers access to tens of thousands of live sporting events annually, alongside news and entertainment content, both live and on demand. Its platform is designed to empower customers to seamlessly access content through streaming devices and on Smart TVs, mobile phones, tablets, and computers. The company offers subscribers a live TV streaming service with the option to purchase incremental features, including additional content or enhanced functionality suited to their preferences. Its subscription packages (including Fubo Essential, Pro, Elite, and others) boast a broad mix of top Nielsen-ranked channels across sports, news, and entertainment. The company operates in a single segment of the streaming business.